Risperidone-associated new-onset diabetes

Biological Psychiatry

Volumn 50, Issue 2, 2001, Pages 148-149

  Wirshing, Donna A ^a,b   Pierre, Joseph M ^a,b   Eyeler, Jerry ^a,b   Weinbach, Julie ^a,b   Wirshing, William C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Diabetes; Obesity; Risperidone; Schizophrenia; Serotonin; Weight

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIET RESTRICTION; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 0035878557     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01087-3     Document Type: Article

References (10)

1. Diabetic ketoacidosis associated with risperidone treatment
2. Treatment of depression in patients with diabetes mellitus
3. Sertraline in coexisting major depression and diabetes mellitus
4. Diphenylhydantoin: Its use in detecting early insulin secretory defects in patients with mild glucose intolerance
5. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case series
6. Effect of diphenylhydantoin on insulin secretion in man
7. Risperidone treatment for a patient suffering from schizophrenia and IDDM
8. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
9. Novel antipsychotics and new onset diabetes
10. Novel antipsychotics: Comparison of weight gain liabilities